A recent phase III trial demonstrated that initial therapy with an immuno-agent improves PFS in patients with HR+, HER2- breast cancer. READ MORE
Research in Review
Clinical Pathways for Breast, Colon, and Rectal Cancers Improve Physician Adherence to Best Practices
Implementation of clinical pathways for breast, colon, and rectal cancers can help narrow the gap between evidence-based treatment guidelines and clinical practice.
Use of the 21-gene recurrence score assay (RS) can help to reduce health care spending and improve breast cancer treatment, but the extent of the benefit offered differs between younger women and those aged 75 years and older.
An observational study of more than 100,000 women with a diagnosis of ductal carcinoma in situ (DCIS, or Stage 0 breast cancer) and published in JAMA Oncology, showed that age and ethnicity are important risk factors for death from breast cancer following a DCIS diagnosis, according to findings that estimated the 10- and 20-year mortality in this patient population.